Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3401) 3401
Publication (250) 250
Book Review (67) 67
Book Chapter (14) 14
Conference Proceeding (5) 5
Magazine Article (5) 5
Book / eBook (3) 3
Dissertation (2) 2
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2434) 2434
index medicus (1714) 1714
male (1624) 1624
female (1341) 1341
muscarinic antagonists - therapeutic use (1170) 1170
animals (946) 946
middle aged (903) 903
muscarinic antagonists - adverse effects (871) 871
pharmacology & pharmacy (861) 861
aged (791) 791
adult (723) 723
muscarinic antagonists - administration & dosage (723) 723
treatment outcome (710) 710
overactive bladder (556) 556
urinary bladder, overactive - drug therapy (523) 523
urology & nephrology (471) 471
rats (441) 441
muscarinic antagonists - pharmacology (437) 437
efficacy (420) 420
double-blind method (403) 403
pulmonary disease, chronic obstructive - drug therapy (396) 396
neurosciences (395) 395
urinary incontinence (394) 394
dose-response relationship, drug (383) 383
drug therapy (368) 368
double-blind (360) 360
care and treatment (319) 319
time factors (309) 309
analysis (304) 304
respiratory system (304) 304
tolterodine (304) 304
safety (299) 299
tolterodine tartrate (292) 292
aged, 80 and over (285) 285
administration, inhalation (276) 276
drug therapy, combination (274) 274
quality of life (271) 271
copd (263) 263
medicine & public health (256) 256
tiotropium (256) 256
oxybutynin (252) 252
lung diseases, obstructive (250) 250
obstructive pulmonary-disease (247) 247
chronic obstructive pulmonary disease (244) 244
adolescent (239) 239
muscarinic receptors (235) 235
mice (227) 227
quality-of-life (223) 223
urinary incontinence - drug therapy (220) 220
benzhydryl compounds - therapeutic use (214) 214
research (210) 210
bronchodilator agents - administration & dosage (208) 208
pulmonary disease, chronic obstructive - physiopathology (207) 207
acetylcholine receptors (205) 205
muscarinic antagonists (205) 205
medicine, general & internal (203) 203
drugs (193) 193
psychiatry (193) 193
dosage and administration (192) 192
severity of illness index (185) 185
young adult (182) 182
cresols - therapeutic use (180) 180
receptors, muscarinic - drug effects (179) 179
benzhydryl compounds - adverse effects (176) 176
solifenacin succinate (175) 175
urology (175) 175
acetylcholine (172) 172
bronchodilator agents - adverse effects (172) 172
receptors, muscarinic - metabolism (171) 171
bronchodilator agents - therapeutic use (166) 166
clinical trials (165) 165
muscarinic antagonists - pharmacokinetics (165) 165
bladder (163) 163
pharmacology/toxicology (162) 162
tolerability (160) 160
therapy (157) 157
scopolamine (156) 156
prospective studies (155) 155
pharmacokinetics (154) 154
pharmacology (154) 154
incontinence (153) 153
drug administration schedule (152) 152
internal medicine (151) 151
randomized controlled trials as topic (151) 151
health aspects (150) 150
receptors (149) 149
symptoms (149) 149
cross-over studies (148) 148
drug combinations (148) 148
rats, sprague-dawley (148) 148
toxicology (148) 148
asthma (147) 147
management (144) 144
urinary-incontinence (144) 144
solifenacin (141) 141
cresols - adverse effects (139) 139
pulmonary disease, chronic obstructive - diagnosis (137) 137
rats, wistar (137) 137
risk factors (135) 135
adrenergic beta-2 receptor agonists - administration & dosage (133) 133
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3321) 3321
German (41) 41
Russian (12) 12
Spanish (12) 12
French (9) 9
Japanese (8) 8
Chinese (4) 4
Swedish (3) 3
Italian (2) 2
Bulgarian (1) 1
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Hungarian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study
by Gray, Shelly L and Anderson, Melissa L and Dublin, Sascha and Hanlon, Joseph T and Hubbard, Rebecca and Walker, Rod and Yu, Onchee and Crane, Paul K and Larson, Eric B
JAMA Internal Medicine, ISSN 2168-6106, 03/2015, Volume 175, Issue 3, pp. 401 - 407
IMPORTANCE: Many medications have anticholinergic effects. In general, anticholinergic-induced cognitive impairment is considered reversible on discontinuation... 
DEPRESSION | MEDICINE, GENERAL & INTERNAL | ALZHEIMERS-DISEASE | OLDER-ADULTS | DRUGS | RISK | SCOPOLAMINE | HEALTH | MILD COGNITIVE IMPAIRMENT | APOLIPOPROTEIN-E | HYPERSENSITIVITY | Alzheimer Disease - etiology | Prospective Studies | Humans | Muscarinic Antagonists - adverse effects | Male | Dementia - epidemiology | Cholinergic Antagonists - administration & dosage | Histamine H1 Antagonists - adverse effects | Muscarinic Antagonists - administration & dosage | Dementia - chemically induced | Antidepressive Agents, Tricyclic - adverse effects | Histamine H1 Antagonists - administration & dosage | Aged, 80 and over | Alzheimer Disease - epidemiology | Female | Aged | Cholinergic Antagonists - adverse effects | Antidepressive Agents, Tricyclic - administration & dosage | Cohort Studies | Medical personnel | Care and treatment | Practice | Dosage and administration | Patients | Risk factors | Parasympatholytic agents | Dementia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)
by Abrams, Paul and Kelleher, Con and Staskin, David and Rechberger, Tomasz and Kay, Richard and Martina, Reynaldo and Newgreen, Donald and Paireddy, Asha and van Maanen, Rob and Ridder, Arwin
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 3, pp. 577 - 588
Abstract Background Combining the β3-adrenoceptor agonist mirabegron and the antimuscarinic (AM) agent solifenacin may improve efficacy in the treatment of... 
Urology | Overactive bladder | Solifenacin | Combination therapy | Mirabegron | OUTLET OBSTRUCTION | TRIAL | THERAPY | URINARY-TRACT SYMPTOMS | MEN | UROLOGY & NEPHROLOGY | TAMSULOSIN | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Urodynamics - drug effects | Male | Muscarinic Antagonists - therapeutic use | Thiazoles - therapeutic use | Adrenergic beta-3 Receptor Agonists - adverse effects | Thiazoles - adverse effects | Urinary Bladder, Overactive - drug therapy | Urological Agents - adverse effects | Time Factors | Urinary Bladder, Overactive - physiopathology | Urination - drug effects | Acetanilides - therapeutic use | Adult | Female | Acetanilides - adverse effects | Urological Agents - therapeutic use | Urinary Bladder, Overactive - diagnosis | Double-Blind Method | Europe | Treatment Outcome | Solifenacin Succinate - therapeutic use | Adrenergic beta-3 Receptor Agonists - therapeutic use | Solifenacin Succinate - adverse effects | Urinary Bladder - physiopathology | Urinary Bladder - drug effects | Aged | Drug Combinations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Pharmacology and therapeutics of bronchodilators
by Cazzola, Mario and Page, Clive P and Calzetta, Luigino and Matera, M. Gabriella
Pharmacological Reviews, ISSN 0031-6997, 2012, Volume 64, Issue 3, pp. 450 - 504
Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of the current management of chronic obstructive pulmonary disease... 
BETA-ADRENOCEPTOR AGONISTS | RANDOMIZED CONTROLLED-TRIALS | OBSTRUCTIVE PULMONARY-DISEASE | METHACHOLINE-INDUCED BRONCHOCONSTRICTION | LONG-ACTING BETA-AGONISTS | ATRIAL-NATRIURETIC-PEPTIDE | INHALED BETA-ADRENOCEPTOR AGONIST | EXERCISE-INDUCED BRONCHOCONSTRICTION | PHARMACOLOGY & PHARMACY | AIRWAY SMOOTH-MUSCLE | GUINEA-PIG TRACHEA | Bronchodilator Agents - therapeutic use | Asthma - metabolism | Xanthines - adverse effects | Humans | Muscarinic Antagonists - adverse effects | Adrenergic beta-Agonists - pharmacology | Bronchodilator Agents - pharmacology | Muscarinic Antagonists - therapeutic use | Xanthines - therapeutic use | Xanthines - pharmacology | Asthma - drug therapy | Drug Discovery | Asthma - genetics | Animals | Muscarinic Antagonists - pharmacology | Adrenergic beta-Agonists - therapeutic use | Pulmonary Disease, Chronic Obstructive - metabolism | Bronchodilator Agents - adverse effects | Adrenergic beta-Agonists - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Pulmonary Disease, Chronic Obstructive - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: The GLOW2 study
by Kerwin, Edward and Hébert, Jacques and Gallagher, Nicola and Martin, Carmen and Overend, Tim and Alagappan, Vijay K.T and Lu, Yimeng and Banerji, Donald
European Respiratory Journal, ISSN 0903-1936, 11/2012, Volume 40, Issue 5, pp. 1106 - 1114
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The... 
Tiotropium | NVA237 | Chronic obstructive pulmonary disease | Long-acting muscarinic antagonist | Bronchodilator | Glycopyrronium bromide | LUNG-FUNCTION | glycopyrronium bromide | tiotropium | SALMETEROL | DECLINE | TRIAL | OBSTRUCTIVE PULMONARY-DISEASE | IMPACT | RESPIRATORY SYSTEM | EXACERBATIONS | long-acting muscarinic antagonist | chronic obstructive pulmonary disease | HEALTH-STATUS | Bronchodilator Agents - therapeutic use | Glycopyrrolate - adverse effects | Double-Blind Method | Glycopyrrolate - therapeutic use | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Muscarinic Antagonists - therapeutic use | Female | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Scopolamine Derivatives - adverse effects | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
by Lipson, David A and Barnhart, Frank and Brealey, Noushin and Brooks, Jean and Criner, Gerard J and Day, Nicola C and Dransfield, Mark T and Halpin, David M.G and Han, MeiLan K and Jones, C. Elaine and Kilbride, Sally and Lange, Peter and Lomas, David A and Martinez, Fernando J and Singh, Dave and Tabberer, Maggie and Wise, Robert A and Pascoe, Steven J and IMPACT Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 18, pp. 1671 - 1680
The frequency of COPD exacerbations during treatment with a triple inhaler — delivering a long-acting beta-agonist (LABA), a long-acting muscarinic antagonist... 
MEDICINE, GENERAL & INTERNAL | OBSTRUCTIVE PULMONARY-DISEASE | IMPACT | PARALLEL-GROUP | DOUBLE-BLIND | TIOTROPIUM | RANDOMIZED CONTROLLED-TRIAL | FLUTICASONE PROPIONATE/SALMETEROL | SALMETEROL | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Benzyl Alcohols - administration & dosage | Hospitalization - statistics & numerical data | Male | Dyspnea - etiology | Quinuclidines - administration & dosage | Chlorobenzenes - administration & dosage | Adrenergic beta-Agonists - administration & dosage | Adult | Female | Bronchodilator Agents - adverse effects | Adrenergic beta-Agonists - adverse effects | Glucocorticoids - adverse effects | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Pulmonary Disease, Chronic Obstructive - complications | Muscarinic Antagonists - administration & dosage | Androstadienes - administration & dosage | Intention to Treat Analysis | Quality of Life | Dyspnea - drug therapy | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Treatment outcome | Lung diseases, Obstructive | Care and treatment | Usage | Analysis | Diagnosis | Inhalers | Pneumonia | Acetylcholine receptors (muscarinic) | Glucocorticoids | Lung diseases | Critical care | Fluticasone | Patients | Quality of life | Medicine | Hospitals | Obstructive lung disease | Population | Chronic obstructive pulmonary disease | Drug dosages | Life Sciences | Human health and pathology | Pulmonology and respiratory tract
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison
by Maman, Khaled and Aballea, Samuel and Nazir, Jameel and Desroziers, Katia and Neine, Mohamed-Elmoctar and Siddiqui, Emad and Odeyemi, Isaac and Hakimi, Zalmai
European Urology, ISSN 0302-2838, 2013, Volume 65, Issue 4, pp. 755 - 765
Abstract Context Overactive bladder (OAB) treatment guidelines recommend antimuscarinics as first-line pharmacologic therapy. Mirabegron is a first-in-class... 
Urology | Antimuscarinics | Systematic reviews | Mixed treatment comparison | Overactive bladder | Mirabegron | TOLTERODINE EXTENDED-RELEASE | SELECTIVE RECEPTOR ANTAGONIST | RANDOMIZED CONTROLLED-TRIAL | NETWORK METAANALYSIS | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | SUPERIOR EFFICACY | PLACEBO-CONTROLLED TRIAL | HEAD-TO-HEAD | ANTIMUSCARINIC AGENT SOLIFENACIN | URINARY-INCONTINENCE | Urinary Bladder, Overactive - drug therapy | Humans | Muscarinic Antagonists - adverse effects | Acetanilides - therapeutic use | Muscarinic Antagonists - therapeutic use | Thiazoles - therapeutic use | Acetanilides - adverse effects | Thiazoles - adverse effects | Urinary incontinence | Comparative analysis | Care and treatment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text LANTERN: A randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
by Zhong, Nanshan and Wang, Changzheng and Zhou, Xiangdong and Zhang, Nuofu and Humphries, Michael and Wang, Linda and Thach, Chau and Patalano, Francesco and Banerji, Donald and LANTERN Investigators
International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)
by Horita, Nobuyuki and Goto, Atsushi and Shibata, Yuji and Ota, Erika and Nakashima, Kentaro and Nagai, Kenjiro and Kaneko, Takeshi
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2017, Volume 2017, Issue 2, p. CD012066
Background Three classes of inhaler medications are used to manage chronic obstructive pulmonary disease (COPD): long-acting beta-agonists (LABA), long-acting... 
INDACATEROL | TWICE-DAILY SALMETEROL/FLUTICASONE | MEDICINE, GENERAL & INTERNAL | ONCE-DAILY QVA149 | TO-SEVERE COPD | UMECLIDINIUM/VILANTEROL | LUNG-FUNCTION | FIXED-DOSE COMBINATION | INDACATEROL/GLYCOPYRRONIUM | FLUTICASONE PROPIONATE/SALMETEROL | SALMETEROL-FLUTICASONE | Pneumonia - etiology | Humans | Muscarinic Antagonists - adverse effects | Administration, Inhalation | Muscarinic Antagonists - therapeutic use | Cause of Death | Disease Progression | Randomized Controlled Trials as Topic | Forced Expiratory Volume | Drug Therapy, Combination - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Adrenergic beta-2 Receptor Agonists - therapeutic use | Quality of Life | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial
by van Kerrebroeck, Philip and Chapple, Christopher and Drogendijk, Ted and Klaver, Monique and Sokol, Roman and Speakman, Mark and Traudtner, Klaudia and Drake, Marcus J and NEPTUNE Study Grp and NEPTUNE Study Group
European Urology, ISSN 0302-2838, 2013, Volume 64, Issue 6, pp. 1003 - 1012
Abstract Background Storage symptoms are particularly bothersome in men with lower urinary tract symptoms (LUTS) but may not be adequately treated by α-blocker... 
Urology | Storage symptoms | Voiding symptoms | Solifenacin | Tamsulosin OCAS | Lower urinary tract symptoms | STORAGE | COMBAT | INTERNATIONAL CONTINENCE SOCIETY | BENIGN PROSTATIC HYPERPLASIA | IMPACT | OVERACTIVE BLADDER | UROLOGY & NEPHROLOGY | BLADDER OUTLET OBSTRUCTION | PLUS | Tablets | Humans | Muscarinic Antagonists - adverse effects | Solifenacin Succinate | Male | Quinuclidines - administration & dosage | Adrenergic alpha-1 Receptor Antagonists - administration & dosage | Absorption | Lower Urinary Tract Symptoms - drug therapy | Adrenergic alpha-1 Receptor Antagonists - adverse effects | Muscarinic Antagonists - pharmacokinetics | Quinuclidines - adverse effects | Double-Blind Method | Administration, Oral | Adrenergic alpha-1 Receptor Antagonists - pharmacokinetics | Tetrahydroisoquinolines - administration & dosage | Tetrahydroisoquinolines - adverse effects | Sulfonamides - pharmacokinetics | Muscarinic Antagonists - administration & dosage | Tetrahydroisoquinolines - pharmacokinetics | Sulfonamides - adverse effects | Aged | Drug Combinations | Sulfonamides - administration & dosage | Quinuclidines - pharmacokinetics | Tamsulosin hydrochloride
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Efficacy and Adverse Events of Antimuscarinics for Treating Overactive Bladder: Network Meta-analyses
by Buser, Nora and Ivic, Sandra and Kessler, Thomas M and Kessels, Alfons G.H and Bachmann, Lucas M
European Urology, ISSN 0302-2838, 2012, Volume 62, Issue 6, pp. 1040 - 1060
Abstract Context Millions of people worldwide experience overactive bladder (OAB), and antimuscarinics are the pharmacologic treatment of choice. Several... 
Urology | Antimuscarinics | Overactive bladder | Efficacy | Adverse events | TOLTERODINE EXTENDED-RELEASE | SELECTIVE RECEPTOR ANTAGONIST | RANDOMIZED CONTROLLED-TRIAL | PHASE-III TRIAL | PROPIVERINE-CONTROLLED TRIAL | MIXED URINARY-INCONTINENCE | DOUBLE-BLIND TRIAL | UROLOGY & NEPHROLOGY | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | NEUROGENIC DETRUSOR OVERACTIVITY | Urinary Bladder, Overactive - drug therapy | Muscarinic Antagonists - therapeutic use | Humans | Muscarinic Antagonists - adverse effects | Urinary incontinence | Complications and side effects | Consulting services | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights